GU Cancers 2024 | The role of urinary comprehensive genomic profiling in managing bladder cancer

Marie-Pier St-Laurent, MD, University of British Columbia, Vancouver, Canada, comments on the potential utility of urinary comprehensive genomic profiling (uCGP) in the management of urothelial carcinoma. The test can detect minimal residual disease (MRD) and in the Phase II SWOG 1605 trial (NCT02844816), patients who were thought have been cleared of cancer were found to have positive uCGP results, triggering further investigation. Dr St-Laurent additionally highlights how uCGP can be incorporated into clinical practice, where high scores can lead to further biopsies and treatment changes. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.